- Home
- CLCO vs MREO Comparison
CLCO vs MREO Comparison
Compare CLCO & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLCO
- MREO
- Stock Information
- Founded
- CLCO 2018
- MREO 2015
- Country
- CLCO United Kingdom
- MREO United Kingdom
- Employees
- CLCO N/A
- MREO N/A
- Industry
- CLCO
- MREO Biotechnology: Pharmaceutical Preparations
- Sector
- CLCO
- MREO Health Care
- Exchange
- CLCO Nasdaq
- MREO Nasdaq
- Market Cap
- CLCO 577.8M
- MREO 577.6M
- IPO Year
- CLCO N/A
- MREO N/A
- Fundamental
- Price
- CLCO $8.81
- MREO $3.72
- Analyst Decision
- CLCO
- MREO Strong Buy
- Analyst Count
- CLCO 0
- MREO 4
- Target Price
- CLCO N/A
- MREO $7.50
- AVG Volume (30 Days)
- CLCO 446.7K
- MREO 804.7K
- Earning Date
- CLCO 11-20-2024
- MREO 11-12-2024
- Dividend Yield
- CLCO 18.61%
- MREO N/A
- EPS Growth
- CLCO N/A
- MREO N/A
- EPS
- CLCO 1.73
- MREO N/A
- Revenue
- CLCO $333,449,000.00
- MREO $1,000,000.00
- Revenue This Year
- CLCO N/A
- MREO $16.39
- Revenue Next Year
- CLCO $11.80
- MREO $9.44
- P/E Ratio
- CLCO $5.31
- MREO N/A
- Revenue Growth
- CLCO N/A
- MREO N/A
- 52 Week Low
- CLCO $8.79
- MREO $1.86
- 52 Week High
- CLCO $13.75
- MREO $5.02
- Technical
- Relative Strength Index (RSI)
- CLCO 24.17
- MREO 41.37
- Support Level
- CLCO $10.44
- MREO $3.18
- Resistance Level
- CLCO $10.86
- MREO $4.40
- Average True Range (ATR)
- CLCO 0.33
- MREO 0.23
- MACD
- CLCO -0.11
- MREO -0.04
- Stochastic Oscillator
- CLCO 0.87
- MREO 44.67
About CLCO Cool Company Ltd.
Cool Co Ltd is a LNG shipping company. The company is engaged in the acquisition, ownership, operation and chartering of liquefied natural gas (LNG) carriers (LNGCs), and the operation of third party fleets under management agreements.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. The Company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).